Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

David S. Alberts, John A. Blessing, Lisa M. Landrum, David P. Warshal, Lainie P. Martin, Stephen L. Rose, Albert J. Bonebrake, Lois M. Ramondetta

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Background: Metastatic and recurrent, platinum resistant cervix cancer has an extremely poor prognosis. The Gynecologic Oncology Group has studied > 20 cytotoxic drugs or drug combinations in the second-line, phase II setting of advanced, drug resistant cervix cancer. Methods: Nanoparticle, albumin-bound paclitaxel (nab-paclitaxel) was administered at 125 mg/m2 IV over 30 minutes on days 1, 8 and 15 of each 28 day cycle to 37 women with metastatic or recurrent cervix cancer that had progressed or relapsed following first-line cytotoxic drug treatment. A flexible, 2-stage accrual design that allowed stopping early for lack of treatment activity was utilized. Because of slow patient accrual, the second stage was not completed. Results: Of 37 patients enrolled, 2 were ineligible due to no prior cytotoxic chemotherapy, which left 35 eligible patients evaluable for response and tolerability. All of the eligible patients had 1 prior chemotherapy regimen and 27 of them had prior radiation therapy with concomitant cisplatin. The median number of nab-paclitaxel cycles were 4 (range 1-15). Ten (28.6%; CI 14.6%-46.3%) of the 35 patients had a partial response and another 15 patients (42.9%) had stable disease. The median progression-free and overall survival were 5.0 and 9.4 months, respectively. The only NCI CTCAE grade 4 event was neutropenia in 2 patients (5.7%) which resolved following dose reduction. Grade 3 neurotoxicity was reported in 1 (2.9%) patient and resolved to grade 2 following dose discontinuation. Conclusions: Nab-paclitaxel has considerable activity and moderate toxicity in the treatment of drug resistant, metastatic and recurrent cervix cancer.

Original languageEnglish (US)
Pages (from-to)451-455
Number of pages5
JournalGynecologic oncology
Volume127
Issue number3
DOIs
StatePublished - Dec 1 2012

Keywords

  • Cervix cancer
  • Drug resistant cervix cancer
  • GOG
  • Nab-paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study'. Together they form a unique fingerprint.

  • Cite this

    Alberts, D. S., Blessing, J. A., Landrum, L. M., Warshal, D. P., Martin, L. P., Rose, S. L., Bonebrake, A. J., & Ramondetta, L. M. (2012). Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecologic oncology, 127(3), 451-455. https://doi.org/10.1016/j.ygyno.2012.09.008